C
linical trials, like all scientific experiments, are guided by protocols that outline the study design, conduct, and analysis. Deviations from the protocol that cannot be scientifically justified are worrisome because they could undermine the validity of the study or analysis. One type of protocol deviation that generates a great deal of concern involves unacknowledged changes to the primary outcome measure. Assumptions about this measure and its distribution underlie the analyses of power and statistical significance. These assumptions depend on prespecification and could be invalidated if the measure were in fact chosen after examination of trial data.
Before 2005, it was taken on trust that a published "primary outcome measure" referred to the measure specified in the protocol, unless otherwise stated. However, after disclosure of several cases in which published measures represented as "prespecified" were actually established "post hoc," it became clear that readers of the literature could be misled.
In an attempt to break this "trust us" status quo, an influential group of journal editors began requiring trial registration at inception (1). One goal was access to key protocol information (including outcome measures) as a way to verify what was reported. (Because protocols change over time for various scientific and other reasons, registration policies allow for the posting and public tracking of changes.) The rates of trial registration at ClinicalTrials .gov soared after implementation of this policy and rose even higher after passage of a federal law requiring trial registration in 2007.
Two recent letters published in Annals (2, 3) show the potential power of registration: Readers questioned apparent discrepancies between ClinicalTrials.gov entries and their corresponding publications (Table) . In 1 publication, the depression scale listed in the registry differed from that used when reporting the results (2). In the other, a vague initial registry entry seemed to differ from the more specific metric used in the publication (3). In effect, the investigators claimed that their initial registry entries did not accurately reflect their initial protocols, but their publications did (4, 5) .
Studies comparing registered and published outcome measures have found discrepancies in up to 49% of trials (6) . Although it is tempting to conclude that these findings reflect scientifically significant protocol deviations, they may in fact result from vague, erroneous, or out-of-date registry entries. This leaves readers of the literature no better off than before registration became widespread.
One major barrier to interpreting registered outcome measures is heterogeneity in levels of specificity (7). To foster analysis and discussion of best practices for reporting outcome measures, we developed a descriptive framework (7) . To illustrate the use of this framework, consider a depression study. One possible measure is the Hamilton Depression Rating Scale, which might seem like an informative registry entry. However, a specific metric for each participant (for example, final score vs. change from baseline) and method of aggregation within each group (for example, mean value vs. percentage with change Ͼ20%) would need to be specified before an actual analysis could be done. Although some believe that each level of specification must be set before trial initiation, others consider it acceptable to wait until data are collected (but before unmasking). To accommodate these varying viewpoints, ClinicalTrials.gov requires only the registration of specific measurements and time frames for outcome measures (such as Hamilton Depression Rating Scale at 12 weeks), although we encourage reporting as much specificity as possible.
Examination of controversial cases that involved possible protocol deviations reveals the potential importance of highly specific registry entries. For instance, ambiguity about the prespecified time frame for a gastrointestinal toxicity measure was a key concern in CLASS (Celecoxib Long-Term Arthritis Safety Study); the statistically significant 6-month data that were published were questioned after it became clear that non-statistically significant 12-month data had been omitted (8) . A proposed change in the specific number and locations for assessing carotid artery intima-media thickness was similarly central to the ENHANCE (Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery) trial (http://clinicaltrials.gov/show/NCT00552097) (9) . These types of deviations could not have been detected by comparing a simple registry entry, such as "intima-media thickness," with a published analysis, because omission of key details would obscure important differences.
As a rule of thumb, we suggest that registry entries parallel the level of specificity described in the protocol by using the framework as a guide (Table) . For example, an initial entry might include only the specific measurement and time frame; however, when fully specified, the entry could be updated to include the particular metric and method of aggregation. These simple procedures would ensure that the registry would reflect the state of the protocol at any given time. As a result, readers and journal editors would be empowered to decide which changes are important, legitimate, or influential with respect to interpreting the results. In addition, the research community could use the registry data for analyzing prevailing practices, perhaps ultimately leading to more refined guidelines.
The infrastructure for universal trial registration is in place, but culture change by all stakeholders (such as investigators, sponsors, journal editors, and readers) is necessary before key goals can be reached. For example, publicly questioning apparent inconsistencies, as these letter authors have done, will remind investigators of their responsibility to register and update trial information. Such disclosures have led to improved registry practices before. Shortly after the journal policy became effective, several industry sponsors were found to be using uninformative phrases in lieu of specific drug names (such as "investigational drug"), thereby undermining the value of registration. The practice effectively ceased after public exposure (10) .
On the other hand, if investigators continue submitting vague, incorrect, or out-of-date entries, we remain stuck when discrepancies are identified among various reports (for example, registry vs. journal article). There will simply be no way to determine whether a source is wrong-or whether there was an unacknowledged deviation from the protocol. In the face of serious concerns about the quality and validity of the medical evidence base, physicians and patients deserve better. "Trust us" is no longer good enough.
